Clifutinib

Clifutinib (HEC73543) is a small-molecule drug developed by Sunshine Lake Pharma. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT05586074 (HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML), in acute myeloid leukaemia. The largest, NCT05586074, plans to enrol 324 participants with primary completion expected 2027-11-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.